Patrik Frei

Dr. Patrik Frei is a prominent faculty member at CELforPharma, where he specializes in the valuation of high-growth companies within the biotechnology and life sciences sectors. He is the Founder and CEO of Venture Valuation, a firm known for its independent assessments and valuations of emerging companies in these fields. Dr. Frei is recognized as one of Europe’s leading experts in this area and has authored the book Assessment and Valuation of High Growth Companies.

In addition to his role at Venture Valuation, Dr. Frei oversees Biotechgate, a global business development database tailored for the life sciences industry. His expertise extends to conducting valuations for significant entities such as the Novartis Venture Fund, highlighting his influence and credibility in the industry .123

At CELforPharma, he leads courses that help professionals understand complex valuation concepts, making them accessible to both beginners and those with more advanced knowledge .12 His teaching approach has received positive feedback for its clarity and effectiveness, helping participants apply valuation principles in practical scenarios .1